October 20, 2020

The Niche

Knoepfler lab stem cell blog

RPEs

1 min read

Advanced Cell Technology (ACT) has confirmed that one of the patient in a clinical trial that it is running for treatment of macular degeneration, the leading cause of blindness worldwide, has shown a striking improvement in vision. The patient reportedly had 20/400 vision prior to treatment and now has 20/40 vision after treatment. ACT uses an embryonic stem cell-based therapy composed of retinal pigmented epithelial cells. The improvement in vision is unlikely to be due to chance, however it is still unclear how promising this …Read More

6 min read

When are iPS cell-based therapies ready to be tested in actual people? It’s the million or perhaps even billion dollar question of today in the stem cell field. I realize that perhaps it is also a dangerous question, politically-speaking, for me to ask in a public forum, but patient lives as well as potentially the progress of the entire iPS cell field are at stake. So someone needs to start an open discussion about this topic. People are certainly talking about it behind the …Read More